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Treatment with buprenorphine represents a promising alternative for pregnant opioid 
addicts but there is a need to understand potential effects on nervous system 
development. We previously showed effects of perinatal exposure to buprenorphine on 
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axonal caliber and myelination in 26-day-old rat corpus callosum. These changes, 
detected at the end of rapid brain myelination and accompanied by earlier 
oligodendrocyte maturation, suggested interference with mechanisms coordinating 
axonal growth and myelination.
To better understand buprenorphine actions and to establish whether these effects 
extend to the spinal cord, we analyzed the corpus callosum and corticospinal tract at 16 
days of age, just before the peak of myelination. Our results point to an important role of 
the opioid system in regulating early axo-glial interactions coordinating axonal growth 
and myelination. Moreover, in addition to reinforcing previous findings in the brain, we 




OPIOID ABUSE AND PREGNANCY
Opioids have been used for centuries in many different cultures for their potent 
analgesic properties. However, epidemiological data clearly demonstrate that these 
drugs are also highly abused. A 2008 study conducted by the Substance Abuse and 
Mental Health Services Administration found that, in the United States, 4.7 million 
adolescents and adults were abusing prescription opioids within the preceding month of 
study (SAMHSA 2009). There has also been an increasing incidence of heroin abuse, 
from 213,000 people in 2007 to 399,000 people in 2009 (SAMHSA 2010). Of greater 
concern is that about 5% of pregnant women abuse illicit drugs (SAMHSA 2008).  Not 
only does this have the potential to harm the mother, but it could also interfere with 
normal development of the unborn fetus.
Studies assessing the potential effects of opioid abuse during pregnancy suggest that in 
utero exposure to these drugs may alter the developing nervous system. For instance, 
the offspring of pregnant addicts show reduced head circumference, developmental 
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delays, altered fine motor coordination, and risk of Sudden Infant Death Syndrome 
(Rosen and Johnson 1982, Kandall et al., 1993). Some of these effects may result in 
cognitive problems since longitudinal studies also show an association between in utero 
opioid exposure and attention deficits (Marcus et al., 1984). However, it is difficult to 
assess the accuracy and validity  of these long-term studies because behavioral and 
cognitive outcomes in children may be strongly affected, both in positive and negative 
ways, by their family and environment.
This thesis project is a continuation of previous studies from this laboratory investigating 
potential alterations of central nervous system (CNS) development induced by 
buprenorphine, a synthetic opioid. As described later, use of this pharmaceutical drug  is 
currently under clinical trials for the treatment of pregnant opioid addicts. 
OPIOIDS
Although the term opioids is often used interchangeably with opiates, the latter are in 
fact defined as natural alkaloids of the opium poppy, and include morphine and codeine. 
Some definitions of opiate, however, also encompass the semi-synthetic derivatives of 
these natural alkaloids, such as hydrocodone and oxycodone. In general, opioids are 
considered to be molecules that can bind to and exert biological functions through 




Initial investigations into the biological effects of exogenous opioids were conducted in 
the hopes of identifying potential receptors involved in the action of these drugs. It 
seemed unlikely, however, that vertebrates would have evolved to develop receptors for 
exogenous ligands (Goldstein et al., 1968). Indeed, experiments conducted in the 1970s 
revealed that the body produces endogenous opioids, and unlike morphine, which is an 
alkaloid, they were classified as peptides (Terenius and Wahlström, 1975, Rosengarten 
et al., 1976). So far, at least twenty  different endogenous opioid peptides have been 
identified as members of three main groups represented by endorphins, enkephalins, 
and dynorphins (Li et al., 1976, Waterfield et al., 1976, Kuhar, 1978, Goldstein et al., 
1979).
Opioid Receptors
These and subsequent studies led to the classification of the G protein-coupled μ, δ, 
and κ-opioid receptors, to which endogenous opioids differentially bind (Lord et al., 
1977). Later studies also identified the nociceptin receptor (NOP). While involved in pain 
management, this receptor does not bind endogenous opioids but instead recognizes 
the endogenous peptide, nociceptin/orphanin FQ (Meunier et al., 1995, Reinscheid et 
al., 1995). While most cells express opioid receptors, these molecules are highly 
enriched in the peripheral and central nervous systems (PNS and CNS, respectively).
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OPIOID MAINTENANCE THERAPY
Substitution treatments for opioid addiction include methadone, a synthetic opioid 
developed in Germany in 1937. Although structurally different (Figure 1), it functions like 
heroin as a μ-opioid receptor agonist, making it generally successful in methadone 
maintenance treatment programs (Sim, 1973). Its potent analgesic properties have also 
deemed it effective in pain management. Moreover, it is currently the standard FDA-
approved drug for the treatment of opioid addiction in pregnant mothers. However, 
methadone is known to cause an increased risk of neonatal abstinence syndrome 
(NAS), which is characterized by, among other things, dysfunction of the 
gastrointestinal, respiratory, and autonomic nervous systems (Finnegan, 1992). 
New opioid addiction treatments employ buprenorphine, a synthetic derivative of 
thebaine that functions as a μ-opioid receptor partial agonist (Martin, 1979) and κ-
receptor antagonist (Leander, 1987). It has also been shown to exert both agonistic and 
antagonistic effects on the δ-opioid receptor (Sadee et al., 1982, Huang et al., 2001). 
This drug has been successfully used in opioid addiction treatment (Mattick et al., 
2008), particularly because the withdrawal effects are less severe than other 
treatments, such as methadone (Jasinski et al., 1978, Martin, 1979, Mello and 
Mendelson, 1980). However, the effects of this drug in utero are widely  unknown, and 
thus, it is not yet FDA-approved for use during pregnancy. Given that buprenorphine 
has been shown to decrease the severity  of NAS in neonates (Jones et al., 2010), the 
prospect of using this drug as a first-line medication for pregnant addicts is promising.
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As already noted, the in utero effects of buprenorphine on the fetus must be further 
studied before it can be safely considered as a substitution therapy for opioid addiction 
during pregnancy. Studies from our collaborator, Dr. Susan Robinson, have shown that 
rat pups, perinatally exposed to a supra-therapeutic dose of buprenorphine, exhibit a 
reduction in the levels of acetylcholine (Robinson 2002b) and neurotrophic factor nerve 
growth factor (Wu et al. 2001) in rat striatum.
More recently, studies from our laboratory have shown that perinatal exposure to 
buprenorphine affects myelination and oligodendrocyte maturation in the developing rat 
brain (Sanchez et al, 2008, Eschenroeder et al., Manuscript under review). Before 
detailing these later results, the following sections will focus on the biology of glial cells 
and myelination.
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Figure 1: The chemical structures of heroin, methadone, and buprenorphine. 
These opioids are clearly structurally different. Still, methadone selectively binds the 
mu-opioid receptor, like heroin. Buprenorphine, however, acts as a mu-opioid receptor 
partial agonist and a kappa-opioid receptor antagonist.
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Neuroglia were first described as “nervenkitt”, or nerve glue, by the German pathologist 
Rudolf Virchow. They differ from neurons by their inability  to conduct action potentials, 
and have generally  been thought of as supporting cells in the brain. In recent decades, 
however, it has become increasingly clear that these cells have functions that extend far 
beyond the simple maintenance and protection of neurons.
In the CNS, there are five types of glia: microglia, oligodendrocytes, astrocytes, 
ependymal cells, and radial glia. Microglia are of mesodermal origin, whereas the other 
glial types, the macroglia, are of ectodermal origin.
Microglia normally exist in a resting state (Penfield, 1925), but under pathological 
conditions, they are transformed into highly phagocytic cells that play a crucial role in 
inflammatory reactions (del Río-Hortega and Jiménez de Asúa, 1921, Penfield, 1925). 
Astrocytes play  a wide variety of functions including the recycling of neurotransmitters 
(Rothstein et al., 1996, Figley and Stroman, 2011), regulation of pH and ionic 
concentration (Sofroniew and Vinters, 2010, Allaman et al., 2011), modulation of 
synaptic plasticity (Christopherson et al., 2005, Barker and Ullian, 2010), and 
participation in the induction and function of the blood-brain barrier (Abbott 2002, 
Hawkins and Davis, 2005, Abbott et al., 2006). Ependymal cells are ciliated cells that 
line the brain ventricles and the central canal of the spinal cord (del Bigio 1995) and aid 
in the production of cerebrospinal fluid (CSF) (Keep  and Jones, 1990). The role of radial 
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glia is primarily  developmental, playing a pivotal role in neuronal migration (Rakic, 1972, 
Edmondson and Hatten, 1987) and, as recently  discovered, in neurogenesis (Noctor et 
al., 2001) and astrocyte generation (Mission et al., 1991). Since oligodendrocytes are 
pertinent to the topic of this thesis, their functions will be discussed in the following 
section.
Oligodendrocytes
The most known role of this CNS cell type parallels that of the PNS Schwann cell; it 
provides insulation to axons in order to increase the conduction velocity of neuronal 
signals via the production of myelin. Unlike a Schwann cell, which provides myelin for 
one internode of one axon, a single oligodendrocyte may myelinate up to 50 axons 
(Hildebrand et al., 1993).
Recently, it has become clear that oligodendrocytes may have other important functions 
besides myelination. Not only  are they thought to signal back and forth with neurons, 
but it has also been suggested that they have an important role in neuronal 
development, survival, and the integration of neuronal networks. For instance, recent 
studies have demonstrated that oligodendrocytes are required for the normal 
development of the cerebellar cortex and the neuronal networks within (Mathis et al., 
2003, Collin L et al., 2004, Doretto et al., 2011). In support of a role in survival, it has 
been found that the loss of gap junction connexins in oligodendrocytes leads to early 
mortality (Magnotti et al., 2011). Moreover, oligodendrocytes can refine neuronal 
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networks through the action of oligodendrocyte myelin glycoprotein (OMgp), which 
inhibits neurite outgrowth at the nodes of Ranvier (Huang et al., 2005).
The Development of Oligodendrocytes
Since the process of myelination is so heavily dependent on oligodendrocyte 
precursors, before we discuss myelin, we must first understand the progressive stages 
of oligodendrocyte development (Figure 2). Oligodendrocyte precursor cells (OPCs) 
arise from neuroepithelial cells of the subventricular region of the brain and spinal cord 
and ultimately differentiate into oligodendrocytes (Rowitch 2004). These cells are 
mitotically  active, migratory, and immunopositive for NG2, which is a chondroitin sulfate 
proteoglycan (Nishiyama et al., 1996, Baumann and Pham-Dinh, 2001). They can be 
characterized as having only one or two processes.
Mediated by  a signal from thyroid hormone, oligodendrocyte progenitors differentiate 
into pre-oligodendrocytes, which are non-migratory and post-mitotic (Almazan et al., 
1985). Unlike their OPC predecessors, pre-oligodendrocytes are immunopositive for the 
O4 antibody against sulfatides (Bansal et al., 1989), as well as for the cytoskeletal 
protein cyclic nucleotide phosphohydrolase (CNP). Even as the cells mature into 
oligodendrocytes, they will continue to express these molecules (Baumann and Pham-
Dinh, 2001). Morphologically, pre-oligodendrocytes have a few more processes than 
OPCs. The complexity of processes increases as the cells mature, and once fully 
differentiated, the cells can be characterized by their expression of the myelin proteins, 
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MBP (myelin basic protein) and PLP (proteolipid protein) (Baumann and Pham-Dinh, 
2001).
Opioid Receptors in Oligodendrocyte Differentiation
In vitro studies of immature oligodendrocytes have demonstrated that activation of the 
μ-opioid receptor enhances the rate of DNA synthesis, and inhibition of the κ-opioid 
receptor increases the size of membrane extensions, which will eventually wrap axons 
in the myelination process (Knapp et al., 1998). Based on these findings, it has been 
suggested that this endogenous opioid system may regulate oligodendrocyte 
differentiation. While studies have demonstrated that the synthesis of endogenous 
opioids occurs in a developmentally-regulated manner (Kanpp  et al., 2001), 
experiments investigating the temporal expression of opioid receptors have  proved to 
be generally inconclusive. Some studies suggest that the expression of μ-opioid 
receptors  precedes that of κ- and δ-opioid receptors (Knapp et al., 1998, Tryoen-Toth 
et al., 2000), while others suggest that these three receptors are expressed throughout 
oligodendrocyte development (Hauser et al., 2009).
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Figure 2: The Development of Oligodendrocytes. This image depicts the progression 
of a precursor cells as it differentiates into a mature oligodendrocytes. The basic 
morphology and markers for each stage of development are depicted, as well as the 










Completely mature oligodendrocytes are capable of producing myelin, a multilamellar 
structure essential to the CNS. As described in detail in the following sections, in the 
CNS, myelin is formed from an outgrowth of the oligodendrocyte membrane that wraps 
around axons, providing electrical insulation. Its lipid-rich and water-poor composition is 
ideal for this function and serves to increase conduction velocity of electrical signals. In 
addition to insulating axons, myelin has been shown to have other significant functions, 
including the maintenance of axons and determination of axonal caliber (Yin et al., 
1998, Brady et al., 1999).
The Structure of Myelin
Myelin is organized such that it forms segments, or internodes, of 150-200 microns 
along the length of the axon separated by unmyelinated points, termed nodes of 
Ranvier (Butt and Ransom, 1989). Sodium channels cluster at these nodes, and are the 
basis of saltatory conduction, which will be explained in a later section.
Electron microscopy (EM) images of axons show alternating concentric electron dense 
and light layers. The dark line is termed the major dense line, and is formed when 
cytoplasmic surfaces of the oligodendrocyte processes come together, which is thought 
to be via the action of MBP (Baumann and Pham-Dinh, 2001). The lighter line is termed 
the minor dense line, or the intraperiod line, and is formed by the apposition of the two 
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outer leaflets, and is thought to be via the action of proteolipid protein (PLP) , a  myelin 
protein (Baumann and Pham-Dinh, 2001). In cross section, EM images of axons 
surrounded by compacted myelin will show the inner extension of the oligodendrocyte 
process, forming the periaxonal layer of myelin. The end of this innermost extension is 
sometimes referred to as the inner leaflet, or the “tongue” (Figure 3) because it contains 
relatively more cytoplasm than the rest of the compact myelin membrane, (Ross et al., 
1962, Seggie and Berry, 1972), from which the cytoplasm has been mostly extruded 
(Sturrock and McRae, 1980). The periaxonal layer is an interesting area to study since it 
directly overlies the axon and is a likely area of axo-glial interactions and signaling.
The Role of Myelin in Action Potential Conduction
In unmyelinated axons, axonal caliber is the major determinant of conduction velocity. In 
these unmyelinated fibers, action potentials are propagated via local circuits (Hodgkin, 
1937a, Hodgkin 1937b, Hodgkin, 1939). Depolarization of an axon is initiated with an 
influx of positively-charged sodium ions via voltage-gated sodium channels, leaving a 
relative negative charge in the local extracellular environment. This internal positive 
charge is sufficient to cause the adjacent intracellular environment to reach threshold 
potential, causing an influx of positive charge here also. Since there are ion channels 
distributed along the axolemma, this process will continue, and the action potential will 
travel down the axon (Firgure 4a).
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A driving evolutionary force to conserve space yet maintain high conduction velocity is 
the development of myelin. Unlike its unmyelinated counterpart, myelinated fibers do 
not have sodium channels along the entire length of the axon. Rather, they are 
restricted to the nodes of Ranvier, the only  points along the axon with axonal membrane 
exposed to the extracellular space. In this way, when there is a depolarization at one 
node, the high membrane resistance of the internode causes the impulse to “jump” to 
the next node for a subsequent depolarization (Lillie, 1925, Huxley and Stämpfli, 1949). 
This process, known as saltatory  conduction, allows for a faster propagation of the 
action potential without an exorbitantly large axonal caliber (Figure 4b).
Myelin Membrane Components and Their Role in Myelination
The dry mass of myelin membrane is 70% lipid and 30% protein. This differs from most 
biological membranes in that myelin has a lesser proportion of protein to lipid. It is this 
fundamental property that gives myelin its hydrophobicity, and along with the existence 
of multiple lamellae, its functional insulation.
The relative proportions of membrane lipids in myelin are unique. Myelin membrane is 
unusually  enriched in cerebroside or galactosylceramide. These galactolipids constitute 
about 30% of the total myelin lipids and they are partially present in their sulfated form, 
sulfatides (Norton and Cammer, 1984). It was originally  thought that these lipids were 
involved in myelin formation, but knockout studies suggested otherwise. The deficient 
animals still form relatively normal myelin, but with age, exhibit hindlimb  paralysis and 
 16
deficits in myelin integrity. This suggested a role in insulation and myelin stability 
(Coetzee et al., 1996). Other major lipids in myelin are cholesterol, ethanolamine 
phosphatides, and lecithin.
Myelin proteins constitute a fifth of the dry  mass of myelin, and several of these proteins 
are specific to myelin. Proteolipid protein (PLP) and myelin basic protein (MBP) together 
make up 80% of myelin proteins, making them the most abundant (Morell et al., 1973).
Alternative splicing of a single gene yields PLP in two isoforms: 20 kDa and 25 kDa. 
PLP has long been implemented in the process of myelin compaction, but PLP knockout 
studies showed that this protein is not required for normal myelin formation. It is 
important to note, however, that the intraperiod line and motor skills of these animals 
are affected (Klugmann et al., 1997), suggesting a role in the maintenance of compact 
myelin.
Several forms of MBP also exist and also result from the alternative splicing of a single 
gene (de Ferra et al., 1985). Together, they  make up 30% of myelin proteins (Boggs, 
2006). The major isoforms, 14kD and 18.5 kD, are localized to the oligodendrocyte 
membrane, whereas the 17 kD and 21.5 kD isoforms are found in the nucleus, 
suggesting a role in the regulation of myelination (Pedraza, 1997). MBP has also been 
shown to have an important role in myelin compaction. Transgenic shiverer mice, which 
are MBP-deficient, exhibit thinner myelin and lack the major dense line in the CNS 
(Privat et al., 1979, Rosenbluth, 1980). Reintroducing the wild-type MBP gene to 
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shiverer mice restores the ability to form compact myelin and major dense lines, 
confirming MBPʼs role in myelin compaction (Readhead et al. 1987).
The extracellular domain of myelin-associated glycoprotein (MAG) is localized to the 
periaxonal space, which is between the first myelin wrap  and the axolemma. As 
suggested by its location, it is thought that MAG facilitates signaling between myelin and 
the axonal membrane (Quarles, 2007). Although there is not much evidence to suggest 
that MAG has a role in myelin formation, it has been implicated in the stabilization of 
myelin and regulation of axonal caliber (Li et al., 1994, Montag et al., 1994, Yin et al., 
1998).
Myelination is a complex process that is extensively studied but still poorly  understood. 
Certainly, the timing of myelination in the CNS appears to be somewhat dependent on 
oligodendrocytes and their precursors in varying stages of development (Yang et al., 
2011). As described above, studies strongly  indicate several myelin components are 
involved in myelin formation and maintenance. There are additional molecules 
expressed by oligodendrocytes that have been implicated in the production of myelin, 
and one such example is the cell adhesion molecule and receptor, α6β1 integrin. This 
molecule can be activated by “outside-in” signals such as extracellular matrix ligands, or 
“inside-out” signals, such as R-Ras. Increasing either of these signals results in 
increased myelin formation (Olsen and Ffrench-Constant, 2005). Despite the extensive 
research conducted to understand how myelin is deposited around axons, much of the 
process is still unknown.
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In this regard, previous studies from our laboratory revealed that exposure to 
buprenorphine during development affects rat brain myelination. Perinatal exposure to 
therapeutic levels of this drug induced accelerated and increased expression of all 
splicing isoforms of MBP, a protein that, as indicated above, is essential for myelin 
compaction and is also a marker of mature oligodendrocytes. In contrast, supra-
therapeutic drug doses delayed MBP expression and also resulted in reduced number 
of myelinated axons in the corpus callosum (Sanchez et al., 2008).
Interestingly, EM images from 26 day old animals showed that regardless of the dose, 
perinatal exposure to buprenorphine results in axons with an increased caliber and a 
disproportionately  thinner myelin sheath. Further experiments demonstrated that the 
buprenorphine-exposed animals also exhibited higher levels of MAG and its interaction 
with the Src-family tyrosine kinase Fyn (Sanchez et al., 2008). 
These findings suggested that exposure to buprenorphine during brain development 
interferes with mechanisms that coordinate axonal radial growth and myelination, 
raising the possibility that endogenous opioid signaling plays a role in their regulation. 
The following section discusses the mechanisms known to regulate axonal caliber, 
including the potential role of myelination.
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Figure 3: An axon surrounded by compacted myelin and the remaining “tongue” 
of cytoplasm. This image was taken from the corpus callosum of a 16 day-old 
buprenorphine-treated female rat. The myelin membrane is already mostly  compacted, 






Figure 4: The propagation of action potentials in unmyelinated and myelinated 
axons. The first image shows how an action potential is propogated via local circuits in 
an unmyelinated axon (a). The second image shows how the insulating capacity of 
myelin membrane forces signals to jump  from node to node, thus increasing conduction 












DETERMINATION OF AXONAL CALIBER
It has long been thought that glial development and axonal growth are “co-regulated” by 
bidirectional axo-glial interaction and signaling. In support of this possibility, maturing 
myelinating axons experience a remarkable increase in axonal radial growth. 
Importantly, this dramatic growth is restricted to the myelinated areas of the axons and 
thus, its induction has been attributed to the myelinating glial cells (Sanchez et al., 
1996).
It is important to note that most studies investigating interactions between axons and 
myelin-producing cells have been conducted in the PNS, mainly because it is 
anatomically  easier to access. Thus, many developments in scientific thought regarding 
these interactions come from examining Schwann cells and the sciatic nerve, which is 
the longest and widest nerve in the body, beginning in the lower back and extending 
down to the lower leg. One such pivotal study was conducted with a trembler 
hypomyelinating mutant mouse, which has a point mutation in the gene for peripheral 
myelin protein 22 (PMP22), and is used as a model for Charcot-Marie-Tooth Disease, 
the most common neuropathy of the PNS. The trembler sciatic nerve exhibited 
decreased axonal caliber as compared with normal animals (Aguayo et al., 1979). 
However, nerve transplantation from wild-type mice suggested that this reduced axonal 
caliber was due to an absence of compact myelin produced by the Schwann cell, and 
not an abnormality of the actual neuron (Aguayo et al., 1979).
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To investigate the CNS, studies were conducted with Shiverer mice, which are mutants 
with a deletion of the MBP gene. Results from these studies suggested that formation of 
myelin by oligodendrocytes is essential to the normal maturation of the cytoskeleton and 
thus, the radial growth of large caliber myelinated axons (Brady  et al., 1999).
How myelinating cells could affect axonal caliber is not fully understood, but under 
normal developmental conditions, this increase in caliber is known to be accompanied 
by local accumulation and phosphorylation of neurofilaments, the intermediate filament 
proteins of the neuronal cytoskeleton (Friede and Samorajski, 1970, Cleveland et al., 
1991, de Waegh et al., 1992, Hsieh et al., 1994, Sanchez et al., 1996).
Neurofilaments are composed of three different subunits, high- (NFH, 180-200 kDa), 
medium- (NFM, 130-170 kDa) and low-molecular weight (NFL, 60-70 kDa) (Shaw et al., 
1982, Lee et al., 1986), which interact through their amino-terminal region via alpha-
helical coils to form the core of the filament (Geisler et al., 1983). In addition, the NFM 
and NFH subunits have long carboxy-terminal regions that generate sidearms 
protruding from the NFʼs core. Numerous phosphorylation sites on these sidearms are 
responsible for the charge-dependent repulsion that occurs between adjacent NFs and 
is thought to be a major determinant of axonal radial growth (Hirokawa et al., 1984, 
Nakagawa et al., 1995). 
As indicated above, altered axonal growth and myelin thickness induced by 
buprenorphine were detected in the corpus callosum at 26 days postnatal (P26), which 
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is an age at which rat brain myelination slows down towards basal adult levels. 
However, it is possible that buprenorphine is (1) exerting its effects on white matter tract 
morphology at an earlier stage of development and (2) that these effects are not limited 
to the brain and may also be detected in the spinal cord. Before we can attempt to 
further our understanding of the timeline and scope of these potential effects, we must 
first discuss the development and myelination of the CNS.
CORPUS CALLOSUM AND SPINAL CORD DEVELOPMENT
The corpus callosum is a commissure of axons that not only  connects the two 
hemispheres of the brain, but also the cortex with the subcortex (Georgy et al. 1993). It 
is comprised of the genu anteriorly and the splenium posteriorly, connected by the body. 
Connected to the genu and lying inferior to the body is the rostrum. The corpus 
callosum is a common area of study for the analysis of CNS axons because (1) it is one 
of the largest concentrations of white matter in the CNS and (2) it is composed of 
parallel axons. Thus, a mid-sagittal section of the brain yields cross-sections of axons 
that can be analyzed for diameter and myelin thickness.
Development of the corpus callosum is such that only rostral fibers have crossed the 
midline by the time of birth (Seggie and Berry, 1972). Early myelination studies of the 
corpus callosum have demonstrated that it is not until between P10-13 that there are 
overt signs of myelination (Seggie and Berry, 1972). In actuality, different areas of the 
brain may begin myelination at different times, but studies with total brain homogenates 
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have shown that on average, it begins at around the aforementioned P10 (Siegel et al., 
2005). This corresponds to a time in oligodendrocyte differentiation when the cells are 
capable of myelinating axons. The peak of myelination is at around P20, when myelin 
accumulation occurs at its maximal rate of 3.5 mg/day (Siegel et al., 2005), and the end 
of rapid myelination occurs in one month-old animals.
The corticospinal tract carries motor information from higher brain centers to 
motoneurons of the body. It begins with pyramidal neurons residing in layer V of 
cerebral cortex, travels ipsilaterally  via the medullary pyramid, and down the 
contralateral spinal cord. This tract is constituted by several components, including a 
dorsal, intermediate, lateral, and ventral component (Goodman et al., 1966, Schreyer 
and Jones 1982).
Compared to other tracts in the rodent spinal cord, the corticospinal tract is late-
developing. Although extension of the tract from the cerebrum begins in embryological 
stages, it does not reach the upper cervical spinal cord until birth (Gribnau et al., 1986), 
and the tract is not fully developed until about P14 (Reh and Kalil, 1981). Myelination, 
however, begins just before the tract has completed its extension at around P10. In a 
one month-old rat, almost half of the axons are already myelinated, and in a three 
month-old rat, one third of the axons remains unmyelinated (Gorgels et al., 1989, 
Gorgels et al., 1990).
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Figure 5: The Rate of Accumulation of Myelin in the Brain. Myelination can be 
detected as early as P1, but on average, myelination begins at around P10. The rate of 
myelin accumulation peaks at P20, at a rate of 3.5 mg/day (Siegel et al., 2005). This 
period of rapid myelination ends at about one month of age, at which point the rate of 
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The purpose of this thesis was to expand our current limited knowledge of the effects of 
buprenorphine on CNS development and in particular, to better understand the timeline 
of buprenorphine actions on axo-glial interactions. As described earlier, previous studies 
in our laboratory have investigated the effects of buprenorphine on 26 day-old animals, 
which corresponds to the end of rapid myelination in rodents.
To build on our previous studies and establish whether the effects of this drug on axonal 
growth and caliber begin earlier in development, we have now used EM to analyze the 
corpus callosum of 16 day-old animals, which corresponds to a time point midway 
between the beginning and peak of rapid myelination. Moreover, at this age, even 
though much of the spinal cord is already myelinated, the corticospinal tract is still in the 
early stages of myelination. We analyzed this tract to determine whether the effects of 
buprenorphine extend to the spinal cord.
Results from the present studies support the involvement of axo-glial interactions in the 
regulation of axonal caliber at an earlier stage of development. Moreover, in addition to 
reinforcing previous findings from our laboratory that suggest a buprenorphine-induced 
acceleration of oligodendrocyte differentiation in the brain, we now propose that this 




The timed-pregnant Sprague-Dawley rats were provided by Harlan Laboratories 
(Frederick, MD). Model 2ML4 Alzet osmotic minipumps were obtained from Durect 
(Cupertino, CA). Buprenorphine was provided by Sigma-Aldrich (St. Louis, MO). The 
Jeol JEM-1230 transmission electron microscope (TEM) equipped with a Gatan 
UltraScan 4000SP 4K x 4K CCD camera are maintained by the VCU Department of 
Anatomy and Neurobiology Microscopy Facility, supported, in part, with funding from 
NIH-NINDS Center core grant (5P30NS047463-02).
BUPRENORPHINE TREATMENT
This study was conducted in accordance with the Guide for the Care and Use of 
Laboratory Animals (Institute of Laboratory  Animal Resources, National Academy Press, 
1996) and under protocols approved by the Animal Care and Use Committee of Virginia 
Commonwealth University. Female rats were implanted subcutaneously with 28-day 
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osmotic minipumps on day 7 of gestation, as previously reported (Sanchez et al., 2008). 
Control animals were implanted with pumps containing sterile water while the 
experimental group  was implanted with pumps delivering 0.3 mg/kg/day of 
buprenorphine in sterile water. In this way, rat embryos began exposure to the drug just 
before the beginning of rapid myelination in the brain. Postnatally, the pups continued 
drug exposure, since buprenorphine passes into the breast milk (Kunko et al., 1996). It 
is important that the pups were exposed to the drug after birth because rats are born at 
a stage of development comparable to the end of the second trimester in human 
pregnancy. Therefore, the administration of buprenorphine postnatally signifies a 
continued exposure to the drug at a critical time in CNS development when 
oligodendrocytes in the brain are rapidly myelinating. The drug dosage was chosen 
because it is equivalent to the treatment dose for humans.
TISSUE PREPARATION
Rats were sacrificed at P16, corresponding to a time point between the beginning and 
peak of myelination in the CNS. In total, eight animals were prepared, two each of 
control males, buprenorphine-treated males, control females, and buprenorphine-
treated females. Animals were anesthetized by intraperitoneal injection with 1 cc of 
2.5% Avertin (tribromoethanol and tertiary amyl alcohol), and when unresponsive to foot 
squeeze, perfused transcardially with phosphate buffer saline (PBS) containing 4% 
paraformaldehyde and 2% glutaraldehyde, in the same buffer, as described previously 
(Dupree et al., 2004). The brains and spinal cords were removed and fixed overnight in 
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the same fixative. Regions of the corpus callosum approximately mid-way between the 
genu and splenium were analyzed as was the dorsal corticospinal tract in the cervical 
spinal cord.  
ELECTRON MICROSCOPY
Cervical spinal cords and brain regions containing the middle portion of the corpus 
callosum were dissected, postfixed with 1% osmium tetroxide in 100 mM sodium 
cacodylate buffer, pH 7.3, and plastic embedded.   Ultrathin sections were collected on 
copper grids and stained with lead citrate and uranyl acetate. They were examined 
using a Jeol JEM-1230 transmission electron microscope equipped with a Gatan 
UltraScan 4000SP 4K x 4K CCD camera. Representative fields from each treatment 
group were photographed at 5,000X magnification, with a minimum of four 17x17 
micron fields per sample. To facilitate identifying the areas of interest in the electron 
microscopy field, one micron thick cross-sections of the regions of interest were 
mounted onto glass slides and stained with toluidine blue.
IMAGE ANALYSIS
Corpus Callosum
Two animals were processed, however axons in the corpus callosum of only  one animal 
from each treatment group were analyzed for diameter, number of myelin wraps and 
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total myelin thickness. The diameter of each axon was determined by  calculating the 
average of the maximal and minimal diameters. To establish the number of myelin 
wraps, we printed and manually counted the number of oligodendroglial membranes 
surrounding the axon, and for partially compacted or compacted axons, this was 
determined by counting the number of major dense lines. From each treatment group, 
between 65-200 axons that exhibited at least one wrap of myelin membrane were 
analyzed for axonal diameter and number of myelin wraps, and for the basis of 
comparison, a sample of unmyelinated axons was also analyzed for axonal diameter. Of 
the axons analyzed for diameter and number of myelin wraps, only those that exhibited 
compacted myelin were analyzed for myelin thickness. Myelin thickness was examined 
in relation to axonal diameter, as represented by the g-ratio, which was calculated by 
dividing the diameter of the axon by the diameter of the axon with myelin membrane 
(Figure 6) (Rushton, 1951).
Corticospinal Tract
Axons in the corticospinal tract (one male per group, two females per group) were 
analyzed for overall degree of myelin compaction. Only axons that exhibited at least one 
wrap of myelin membrane were analyzed for each of these parameters. Since 
myelination in the spinal cord precedes that of the corpus callosum, there were many 
more axons in the corticospinal tract that were surrounded by myelin membrane and 
could thus be analyzed for degree of myelin compaction. Between 280-374 axons were 
analyzed for each treatment group. Axons were assigned to one of the following groups: 
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(1) one wrap of myelin membrane, (2) multiple but uncompacted wraps of myelin 
membrane, (3) partially compacted membranes, or (4) fully  compacted myelin 
membranes. These categories are further defined in the “Results” section. The 
percentage of axons within each of these groups was calculated and compared 
between each treatment group.
STATISTICAL ANALYSIS
Statistical analysis was performed by one-way analysis of variance using the GraphPad 
Prism program. When the p-values were less than 0.05, the differences between groups 
were considered statistically significant.
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Figure 6: Measurements to determine the g-ratio. The g-ratio is the diameter of the 
axon (A) divided by the diameter of the axon with myelin (B). A larger g-ratio represents 
a thinner myelin sheath relative to the diameter of the axon, and a smaller g-ratio 
represents a thicker myelin sheath relative to the diameter of the axon.
 36
 37
Exposure to buprenorphine also results




               A (diameter of naked axon)
G ratio =  ---------------------------------------
               B (diameter of axon + myelin)
RESULTS
ANALYSIS OF BUPRENORPHINE EFFECTS ON AXONAL RADIAL GROWTH AND 
MYELIN FORMATION AT EARLY STAGES OF CORPUS CALLOSUM MYELINATION
As described previously, earlier studies from our laboratory conducted on 26 day-old 
animals have found that perinatal exposure to a supra-therapeutic dose of 
buprenorphine reduces the number of myelinated axons in the corpus callosum 
although no differences in this regard were detected in the animals exposed to a 
therapeutic dose of the drug. However, regardless of the buprenorphine dose, 
myelinated axons in both experimental groups exhibited increased caliber and a 
disproportionately thinner myelin sheath (Sanchez et al., 2008).
At P26, the rate of myelination in the rat brain has already begun decrease, 
approaching basal adult levels. This raised the question of whether those changes in 
axon morphology and myelination induced by buprenorphine could be seen earlier in 
development. Answering this question should help to further understand buprenorphine 
effects and provide important clues on the role of opioids in regulating myelination and 
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axo-glial interactions. We therefore decided to analyze the corpus callosum of animals 
at 16 days of age, a developmental time point that immediately precedes the peak of 
myelination and at which very few axons are already myelinated (Figure 7).
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Figure 7: Electron micrograph of corpus callosum from 16 day-old 
buprenorphine-treated female rat. At this stage of development in the corticospinal 
tract, the majority of axons are unmyelinated, and there are very  few axons that exhibit 












Based on our previous findings, we first investigated if pups exposed to a therapeutic 
dose of buprenorphine exhibited at this earlier age any discernible alterations in the 
diameter of axons in function of the number of myelin wraps. 
As shown in Figure 8, for both controls and buprenorphine-exposed animals at 16 days 
of age, there is a gradual increase in axonal diameter with an increased number of 
wraps. For both males (Figure 8a) and females (Figure 8b), axons with one wrap of 
myelin exhibit significantly larger diameters than those axons which are unmyelinated (p 
< 0.0001). Moreover, axons with three wraps of membrane exhibited diameters that 
were at least twice as large as unmyelinated axons. However, a comparison between 
axons with equal number of wraps across the experimental groups did not indicate any 
significant differences between controls and buprenorphine-treated animals at this age 
of development.
Interestingly, when an “average axonal diameter” was calculated excluding those axons 
that were unmyelinated or had only  one wrap  of myelin (Figure 9), buprenorphine 
exposed females exhibited a modest but nevertheless significant increase in the caliber 
of myelinated axons. In contrast, while the numerical average was also higher for the 
treated males, the differences were not statistically significant.
These observations suggest that the greater buprenorphine effects previously observed 
in the 26-day-old animals could result from a progressive drug effect that begins with 
myelination but extends far beyond the initial steps of axo-glial interaction.
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Figure 8: Correlation between the number of wraps and axonal diameter in the 
corpus callosum. As described under in “Materials and Methods”, the corpus callosum 
of 16 day-old animals was analyzed by electron microscopy for axonal diameter and the 
number of wraps. The graph depicts the results obtained by analysis of 65-200 axons 
for each treatment group  (control males, control females, buprenorphine-treated males, 
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Figure 9: Female pups exposed to buprenorphine exhibit  a larger average axonal 
diameter. Mid-sagittal sections of the corpus callosum from male and female 16 day-old 
controls and buprenorphine-exposed animals were analyzed for axonal diameter as 
described in “Materials and Methods”. The average diameter of axons with two or more 
wraps was calculated for each treatment group. *p < 0.04.
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Since previous studies with 26-day old animals indicated that buprenorphine exposure 
also resulted in a disproportionally thinner myelin sheath (Sanchez et al., 2008), we 
attempted to determine g-ratios at 16 days of age to establish whether the same 
buprenorphine effect was already observed at this earlier stage of development. As 
described in the Materials and Methods section, to calculate the g-ratio, the diameter of 
the axon was divided by  the diameter of the axon with myelin sheath (Rushton 1951). 
Only  axons that exhibited compacted myelin were considered for this particular 
analysis.
In contrast with the results obtained from the studies conducted in the older animals, a 
comparison between buprenorphine-treated animals and controls at P16 shows no 
significant difference in g-ratio for either sex (Figure 10). These new results suggest that 
at this age, buprenorphine exposure may not yet affect the molecular mechanisms 
underlying the determination of an optimal g-ratio.
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Figure 10: There is no significant  difference in corpus callosum g-ratios between 
controls and buprenorphine-treated animals at P16. As described in “Materials and 
Methods”, axons with compacted myelin in the corpus callosum were analyzed, and g-















EXPOSURE TO BUPRENORPHINE RESULTS IN A LARGER PROPORTION OF 
AXONS IN THE CORTICOSPINAL TRACT THAT EXHIBIT COMPACTED MYELIN
Previous research from our laboratory focused on the effects of buprenorphine in the 
brain (Sanchez et al, 2008; Eschenroeder et al, Manuscript under review). We now 
decided to extend these studies to the spinal cord, analyzing the corticospinal tract. 
Myelination of this tract occurs before than in axons of the corpus callosum, beginning 
at P10 (Gorgels et al., 1989, Gorgels et al., 1990). As shown in Figure 11, at P10, 
oligodendrocytes in this tract contain abundant cytoplasm and cell processes highly 
enriched in mitochondria, rough endoplasmic reticulum, and golgi apparatus, all 
characteristics of actively myelinating cells.  
The corticospinal tract was analyzed for degree of myelin compaction, such that any 
axon that exhibited at least one wrap of myelin was placed into one of the following four 
categories depicted in Figure 12: one wrap of myelin, “uncompacted” myelin, “partially 
compacted” myelin, or compacted myelin. Placement of axons into each of these 
categories was based on the following criteria:
(1) an axon surrounded by a single wrap  of oligodendrocyte process was 
characterized as having one wrap of myelin membrane,
(2) an axon surrounded by myelin membrane that appeared to be less than 40% 
compacted was described as having “uncompacted” myelin,
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(3) an axon with myelin membrane that appeared to be between 40-60% 
compacted was termed as having “partially compacted” myelin, and
(4) an axon exhibiting myelin with more than 60% compaction was categorized 
as an axon with compacted myelin (Figure 12).
We analyzed the relative distribution of axons within each of these categories by 
counting the total number of axons that exhibited at least one wrap of myelin, and then 
expressed the results for each group as a percentage of this total.
 51
Figure 11: Electron micrograph of the corticospinal tract  in a buprenorphine-
treated 16 day-old female rat pup. Notice the presence of an oligodendrocyte 
engaged in active myelination. This cell is characterized by the presence of abundant 
cytoplasm and multiple mitochondria-enriched cell processes that are interacting with 














Figure 12: The categories describing the degree of myelin compaction of axons in 
the 16 day-old rat  corticospinal tract. The top row depicts an entire axon while the 
bottom row illustrates the interface of the axonal and glial membranes. (a) an axon 
surrounded by a single wrap  of oligodendrocyte process was characterized as having 
one wrap  of myelin membrane, (b) an axon surrounded by myelin membrane that 
appeared to be less than 40% compacted was described as having “uncompacted” 
myelin, (c) an axon with myelin membrane that appeared to be between 40-60% 
compacted was termed as having “partially compacted” myelin, and (d) an axon 
exhibiting myelin with more than 60% compaction was categorized as an axon with 
compacted myelin.
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As depicted in Figure 13, we found that there is a greater proportion of axons 
surrounded by compacted myelin in animals exposed to buprenorphine. Analysis within 
each experimental group  indicated that for control animals, there is a similar proportion 
of both axons with "partially compacted" and compacted myelin. However, the 
proportion of axons with "uncompacted" myelin was significantly larger than either of the 
other two categories. Interestingly, this is in sharp contrast with the results for the 
animals exposed to buprenorphine. In these pups the percentage of axons with 
"partially  compacted" myelin was, like the controls, about 25 %. However, at difference 
with the controls, the number of axons with compacted myelin in the drug-exposed 
animals reaches the proportion of those with "uncompacted" membrane and moreover, 
significantly surpasses that of axons  with “partially compacted” myelin (p < 0.002).
Since compact myelin may also be considered as a sign of more mature 
oligodendrocytes, these results are consistent with previous findings from our laboratory 
that suggest that exposure to a therapeutic dose of buprenorphine accelerates the 
differentiation of oligodendrocytes (Sanchez et al., 2008, Eschenroeder et al., 
Manuscript under review). 
As shown in Figures 14 and 15, the findings described above are also similarly  detected 
when the proportion of axons at different stages of myelination is separately  analyzed in 
from the male pups or female pups. Each sex also showed that buprenorphine-exposed 
animals have a larger proportion of axons with compacted myelin as compared to 
controls. Nevertheless, males and females exhibited some minor differences. Unlike the 
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buprenorphine-treated males (Figure 14), analysis of the buprenorphine-treated females 
(Figure 14) showed that the proportion of axons with compacted myelin, although 
numerically  higher, is not significantly greater than the proportion of axons that exhibit 
“partially compacted” myelin. It is important to note that the data for each treatment 
group was based on four 17x17 micron images with 72-107 axons analyzed in each 
(total of 280-374 axons per treatment group). Thus, the greater statistical significance of 
the larger number of data for the combined sexes than for each sex alone suggests that 
such difference between the sexes may diminish with a larger sample size. 
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Figure 13: Buprenorphine exposure results in a larger proportion of axons with 
compacted myelin in the corticospinal tract. Electron micrographs of the 16 day-old 
corticospinal tract were analyzed for the degree of myelin compaction. The relative 
proportions of each category was determined for buprenorphine-treated animals and 
controls. *p < 0.002, **p < 0.0001.
    

























p < 0.0001 “Uncompacted” vs. 
Compacted
NS
“Partially Compacted” vs. 
Compacted




Figure 14: Buprenorphine exposure results in a larger proportion of axons with 
compacted myelin in the male corticospinal tract. As described previously in 
“Materials and Methods”, the corticospinal tract of 16 day-old male rat pups were 
analyzed for degree of myelin compaction, and the relative proportions of each category 
were calculated. *p < 0.007, **p < 0.003, ***p < 0.0006.
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Figure 15: Buprenorphine exposure results in a larger proportion of axons with 
compacted myelin in the female corticospinal tract. Axons in the female 
corticospinal tract were studied, and those exhibiting at least one wrap of myelin were 
placed into one of the following categories: one wrap of myelin, “uncompacted” myelin, 
“partially compacted” myelin, or compacted myelin. The relative proportions of each 
were computed and graphed. *p < 0.02, **p < 0.009.
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The differences between the buprenorphine-treated males and females and their 
respective controls is perhaps better observed in Figure 16. This comparison more 
clearly  demonstrates that animals exposed to buprenorphine have a greater proportion 
of axons with compacted myelin. 
As shown in Figure 16, controls and buprenorphine-treated animals exhibit no 
difference in the proportion of axons with either a single myelin membrane wrap  or 
“partially compacted” myelin. However, animals exposed to buprenorphine exhibited a 
significantly lower percentage of axons with “uncompacted” myelin, mirrored by a 
similarly significantly  higher percentage of axons with compacted myelin. The increase 
in the proportion of axons exhibiting compacted myelin supports the previously 
observed effects of buprenorphine exposure on oligodendrocyte maturation.
Results from analysis of only the male pups showed that exposure to buprenorphine 
caused a decrease in the proportion of axons with “uncompacted” myelin and an 
increase in the proportion of axons with compacted myelin (Figure 17a). Although 
analysis of female pups also yielded a lower proportion of axons with “uncompacted” 
myelin in buprenorphine-treated animals, Figure 17b shows that there was no difference 
in the proportion of axons with compacted myelin (p = 0.19). Relative to each sex 
individually, the combined data from the female and male animals demonstrated more 
significant differences between control and buprenorphine-treated groups. This supports 
the idea that a greater sample size could perhaps yield more significant results.
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Figure 16: Buprenorphine exposure results in a lower proportion of axons with 
“uncompacted” myelin and a larger proportion of axons with compacted myelin. 
Samples of the corticospinal tract were prepared as described in “Materials and 
Methods” and analyzed for degree of myelin compaction as described earlier in 






































Figure 17: Buprenorphine-treated 16 day-old rats exhibit a greater proportion of 
axons with compacted myelin. Axons in the corticospinal tract of 16 day-old rat pups 
were analyzed by  electron microscopy and characterized according to the four stages of 
myelination described earlier in this section (See Figure 12). The relative proportions 
were of each were compared between controls and buprenorphine-treated animals. (a) 








































































































Buprenorphine has long been considered a successful substitution therapy for opioid 
addiction, but its use in pregnant addicts is still under speculation. Although methadone 
is already an FDA-approved treatment for this condition, the associated increased risk 
of neonatal abstinence syndrome (NAS) begs the pursuit of research into alternative 
therapies (Finnegan, 1992). Buprenorphine is an attractive solution because, in addition 
to its efficacy in non-pregnant addicts, it has been found to decrease the severity  of 
NAS (Jones et al., 2010). In general, however, there is limited knowledge of the in utero 
effects of this drug. Exposure to other opioids has been shown to cause developmental 
delay, altered fine motor skills, and attention deficit (Rosen and Johnson, 1982, Marcus 
et al., 1984). Thus, it is important to thoroughly understand the potential effects of 
buprenorphine on the development of the CNS before it can be established as a first-
line treatment for pregnant opioid addicts.
Previous studies from our laboratory have indicated that perinatal exposure to 
buprenorphine affects axonal diameter, myelination, and oligodendrocyte maturation in 
the developing rat brain (Sanchez et al., 2008, Eschenroeder et al., Manuscript under 
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review). The corpus callosum of 26 day-old animals that were perinatally exposed to 
buprenorphine exhibited larger caliber axons and disproportionately thinner myelin 
sheaths. This was accompanied by changes in MBP expression, suggesting that the 
drug alters the timing of oligodendrocyte differentiation (Sanchez et al., 2008).
The present studies investigated the relationship between the extent of myelination and 
axonal diameter, and potential actions of buprenorphine at postnatal day 16, an age that 
immediately precedes the peak of rapid myelination in the corpus callosum. This 
allowed us to assess the effects of buprenorphine at the early stages of axo-glial 
interaction and subsequent myelination.
As described in the “Results” section, as axons are surrounded with additional myelin 
lamellae, there is an increase in axonal diameter in both controls and buprenorphine-
treated animals. Also true for both experimental groups is that axons with just one wrap 
of myelin membrane already have a significantly larger diameter than unmyelinated 
axons, and those axons with three or more wraps of myelin membrane exhibit axonal 
diameters that are at least twice the size of their unmyelinated counterparts. 
Interestingly, analysis of the average diameter of axons with at least two wraps of 
myelin indicates that at this earlier age, buprenorphine-treated females already  exhibit a 
higher average axonal diameter than control animals. Although the absolute numerical 
average was also higher for the buprenorphine-exposed males as well, it was not 
statistically significant. In spite of the differences in axonal diameter, analysis of g-ratios 
 70
shows no significant differences between controls and buprenorphine-treated animals, 
suggesting that drug effects on myelin thickness occur later in the myelination process.
There are several lines of evidence indicating that larger caliber axons exhibit thicker 
myelin sheaths in the nervous systems of many different animal species (Friede and 
Samorajski, 1967, Friede and Samorajski, 1968, Hildebrand and Hahn, 1978). These 
early studies examined the relationship between axonal diameter and either myelin 
thickness or the number of myelin lamellae. The present results demonstrating an 
increase in axonal diameter with an increased number of myelin wraps is consistent 
with these previous findings. Additionally, there is evidence to support the idea that 
compact myelin is required for radial growth (Brady et al., 1999). Since axons that 
exhibit more wraps of myelin are more likely to exhibit compact myelin (Seggie and 
Berry, 1972), it is possible that a more profound presence of compact myelin in larger 
caliber axons may also be influencing radial growth in axons of the corpus callosum.
However, previous papers have also demonstrated the importance of the initial axo-glial 
interactions as a determinant of axonal diameter (Hildebrand et al., 1985, Windebank et 
al., 1985, Colello et al., 1994, Hsieh et al., 1994, Sanchez et al., 1996). It has been 
shown that shiverer mutant mice, whose oligodendrocytes have the ability to wrap 
axons but do not form myelin, still exhibit axons with normal caliber. This study was of 
particular importance because it demonstrated that it was the early axo-glial interaction 
and not necessarily the presence of compact myelin that regulated axonal caliber 
(Sanchez et al., 1996). Based on this literature, for both controls and buprenorphine-
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exposed pups, the observed larger caliber of axons with one wrap  of myelin membrane 
versus those axons that were unmyelinated could be due to initial contact from an 
oligodendrocyte. 
Although there is much evidence to support the idea that axo-glial interactions are 
occurring and affecting radial growth of axons, the mechanism of communication is still 
not fully understood. The myelin glycoprotein MAG was originally investigated as a 
potential molecule involved in axo-glial communication due to its location within the 
layer of myelin directly overlying the axon (Trapp  and Quarles, 1984). MAG has since 
been implicated in bidirectional axo-glial signaling resulting from the initial contact of 
myelinating cells and axons, triggering active myelination and the regulation of axonal 
caliber (Yin et al., 1998, Quarles, 2007). As defined by its classification as a 
glycoprotein, MAG is heavily  glycosylated, and changes in its glycosylation have been 
associated with early  stages of myelination (Bartoszewicz et al., 1995). Additionally, 
MAG has been shown to interact with the Src-family tyrosine kinase Fyn early in the 
myelination process, by means of phosphorylation sites within its cytoplasmic domain, 
resulting in downstream signaling cascades in the oligodendrocyte (Jaramillo et al., 
1994, Umemori et al., 1994, Fujita et al., 1998).
In this regard, it is important to point out that previous studies from our laboratory 
showed that the brain of 12 day-old rat pups that were perinatally  exposed to 
therapeutic levels of buprenorphine exhibited elevated levels of MAG glycosylation. 
Moreover, co-immunoprecipitation studies at this early age indicated increased 
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interaction of MAG with Fyn (Sanchez et al, 2008). Notably, comparison with the control 
group indicated that MAG protein levels in buprenorphine-exposed animals were also 
elevated throughout the peak of myelination at 19 day postnatal and even at the end of 
rapid myelin formation at around one month of age.
Thus, it is possible that the increase in average axonal diameter observed in the present 
studies in buprenorphine-treated females could be due to altered MAG glycosylation 
and association of MAG with Fyn early in the myelination process. Since this change in 
MAG glycosylation is not seen in 19 day-old animals, it can be speculated that 
buprenorphine affects axonal caliber via the alteration of mechanisms involving MAG at 
the beginning of myelination, and perhaps these effects gradually  taper off before they 
reach the peak of rapid myelination. It is yet to be determined whether there are 
buprenorphine-induced changes in MAG expression, glycosylation, and association with 
Fyn at 16 days of age, and studies investigating this would have to be conducted to 
verify or disprove this hypothesis.
Despite the existence of compelling evidence indicating that axo-glial interactions are a 
major determinant of axonal caliber, accompanied by the previous and present results 
suggesting that buprenorphine may indeed influence these events, the cascade of 
molecular mechanisms leading to increased axonal diameter are not fully understood. 
As described above, it is thought that these changes are mediated by  MAG, and it is 
also known that there are intrinsic elements within the neuron that affect axonal caliber 
(Elder et al., 2001). More specifically, the axonal cytoskeleton is thought to play an 
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important role in regulating axonal caliber in both the CNS and the PNS (Friede and 
Samorajski, 1970, de Waegh et al., 1992, Sanchez et al., 1996, Sanchez et al., 2000).
Early studies showed that the number and density of NFs in axons affects axonal 
caliber, such that either a larger accumulation of NFs or greater NF spacing results in 
radial growth (Friede and Samorajski, 1970, de Waegh et al., 1992). The NFM and NFH 
subunits possess multiple phosphorylation sites on sidearms extending from the c-
terminal regions. It is thought that when phosphorylated, repulsion between the negative 
charges increases NF spacing, resulting in larger axonal diameter (Hirokawa et al., 
1984, Nakagawa et al., 1995).
This phosphorylation-dependent mechanism assumes the existence of NF kinase-
phosphatase systems subjected to regulation by extrinsic factors (de Waegh et al., 
1992, Sanchez et al., 2000). One of these factors could be MAG, as this glycoprotein 
has been implicated in axo-glial interactions, and MAG-deficient mice exhibit a reduction 
in axon caliber, NF spacing, and NF phosphorylation (Yin et al., 1998). Moreover, 
experiments in which MAG-expressing COS cells were co-cultured with dorsal root 
ganglion neurons demonstrated a direct role of this glycoprotein in regulating not only 
NF levels and phosphorylation but also the expression and activity of extracellular-
signal regulated kinases (ERK 1/2) and cyclin-dependent kinase-5 (cdk5), which have 
been implemented in cytoskeletal protein phosphorylation (Dashiell et al., 2002).
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Several lines of evidence, however, indicate that signaling between axons and glial 
cells, however, is not unidirectional. It has long been thought that there is a minimum 
axonal caliber that is necessary for myelination (Duncan 1934). Nevertheless, a direct 
causative correlation between axonal caliber and the resulting myelin sheath is not clear 
and furthermore, different mechanisms may underlie the final myelin thickness achieved 
for axons within the PNS and CNS. Support for this possibility stems from studies 
conducted on mouse mutants characterized by reduced axonal calibers resulting from a 
deficiency of NFs. In these animals, axons of the PNS exhibited disproportionally and 
abnormally  thick myelin. In the spinal cord, however, the thickness of the myelin sheath 
was proportional to the small caliber of the axons. These results suggested that in the 
oligodendrocytes and Schwann cells respond to different cues and while axonal caliber 
is a determinant factor for myelin thickness in the CNS, this is not the case in the PNS 
where Schwann cells may read other intrinsic signals controlling myelin formation (Elder 
et al., 2001).
It is important to consider these data when discussing the g-ratio, which is a numerical 
value that describes the well-documented positive relationship between axonal caliber 
and myelin thickness. The g-ratio, which represents optimal axonal myelination, is 
highly conserved (Chomiak and Hu, 2009). There is a functional advantage to 
possessing a larger axonal caliber and thicker myelin, because both of these factors 
increase signal conduction velocity. However, nerve fiber growth is limited by the 
amount of space in the nervous system, and thus the g-ratio represents a compromise 
between optimal function and spatial constraints (Chomiak and Hu, 2009). For the PNS, 
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the optimal g-ratio is 0.6, while for the CNS, this value is 0.77 (Rushton 1951, Chomiak 
and Hu, 2009). 
Previous studies from our laboratory  demonstrated elevated g-ratios in the corpus 
callosum of 26 day-old animals perinatally exposed to buprenorphine (Sanchez et al., 
2008). However, we did not detect any significant g-ratio differences in the 16 day-old 
animals. This could be due to the difficulties encountered in attempting to calculate g-
ratios at this earlier age. In support of this possibility, several lines of evidence have 
indicated that the correlation between axonal diameter and myelin thickness is less 
obvious in immature axons (Friede and Samorajski 1967, Friede and Samorajski, 1968, 
Fraher, 1972). Moreover, at this younger age, very few axons exhibited compact myelin, 
which is a requirement for determining g-ratio.
However, it is equally possible to speculate that at this age, buprenorphine has not yet 
affected the mechanisms underlying the determination of g-ratio. Since these 
mechanisms are poorly  understood, it is difficult to postulate exactly how buprenorphine 
could be exerting its effects. Yet, axonal diameter has been shown to affect myelin 
thickness (Elder et al., 2001). Thus, the earlier postulation that buprenorphine may be 
directly affecting cytoskeletal elements, and not indirectly through MAG, becomes more 
plausible. Alternatively, buprenorphine may be affecting some unidentified growth factor 
or signaling molecule that is expressed within the axon as the caliber increases, 
disrupting the mechanisms that consequently influence myelin thickness.
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As described above, radial growth of axons in the mammalian nervous system is an 
apparently extremely  complicated process, and although we know that axo-glial 
interactions, MAG, and cystoskeletal elements are involved, it is certainly not this 
simple. For instance, sulfatides, which are galactolipids particularly abundant in myelin, 
have been shown to also affect axonal caliber (Marcus et al., 2006). Additionally, 
compact myelin is supposedly required for radial growth of axons (Brady et al., 1999), 
but the mechanisms are widely unknown. The process is further complicated by the 
existence of bi-directional signaling between axons and glia, such that it is difficult to 
decipher whether observed changes in animal models are the result of effects on glia, 
axons, or a combination of both. Given the limitations in our current understanding of 
these mechanisms, investigation into how buprenorphine affects such mechanisms 
proves to be difficult, but may at the same time, shed light on this interesting problem.
The corpus callosum, however, represents just one area of the central nervous system 
that was analyzed in these studies to assess the effects of buprenorphine on 
myelination and axonal morphology. At 16 days of age, the corticospinal tract, which 
carries motor information from the cerebral cortex to the body, is also in the early stages 
of myelination (Gorgels et al., 1989).
The present results obtained from analysis of the 16 day-old rat corticospinal tract 
indicate that perinatal exposure to buprenorphine does not alter the proportion of axons 
that exhibit either just one wrap  or “partially compacted” myelin. However, we found that 
in the buprenorphine-treated animals, there is a lower proportion of axons that exhibit 
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“uncompacted” myelin. Remarkably, this was accompanied by a complementary higher 
proportion of axons that are ensheathed by already compacted myelin.
We hypothesize that the buprenorphine-induced changes in compaction could be due to 
changes in oligodendrocyte differentiation, as increased compact myelin may be a sign 
of more mature oligodendrocytes (Readhead et al., 1987). In support of this possibility, 
previous studies from our laboratory have demonstrated that perinatal exposure of 
animals to a therapeutic dose of buprenorphine results in early expression and 
increased brain levels of MBP, a sign of accelerated oligodendrocyte maturation 
(Sanchez et al., 2008). Furthermore, direct treatment of cultured oligodendrocytes with 
low buprenorphine concentrations does not only result in elevated MBP levels but also 
in augmented formation of membrane extensions and increased complexity  of the cell 
processes, all characteristics of more mature oligodendrocytes. Additional experiments 
showed that, at least in culture, these stimulatory effects of buprenorphine reflected a 
novel role of the μ-opioid receptor as a positive modulator of oligodendrocyte 
development (Eschenroeder et al, Manuscript under review). This is in contrast to 
previous studies which only suggested a role for this receptor at earlier stages of cell 
development, functioning as a stimulator of proliferation in both neonatal 
oligodendrocyte progenitors (Knapp  and Hauser, 1996) and adult neuroprogenitors 
(Persson et al., 2003). However, regardless of the effect, the precise mechanisms 
downstream of μ-opioid receptor activation are still poorly understood. 
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In this regard, unpublished recent observations from our laboratory showed that doses 
of buprenorphine that stimulate oligodendrocyte development also elicit in these cells an 
early transient increase in the phosphorylation of CREB (cyclic AMP response element 
binding protein). CREB, a member of the leucine zipper family  of transcription factors, is 
activated by phosphorylation and subsequently binds to the consensus sequence 
known as CRE (Ca2+/cyclic AMP-response element). Interestingly, it has been found 
that several neurotransmitters and signal transduction pathways stimulate CREB 
phosphorylation at different stages of oligodendrocyte development (Pende et al., 1997, 
Sato-Bigbee et al., 1999). In immature oligodendrocyte progenitors, for instance, CREB 
plays a crucial role in the stimulation of cell proliferation (Johnson et al., 2000) and 
survival (Saini et al., 2004, Saini et al., 2005) induced by neurotrophin-3 (NT-3), directly 
regulating the expression of the anti-apoptotic gene Bcl-2 (Saini et al., 2004). 
Interestingly, at a later developmental stage when the cells are pre-oligodendrocytes, 
CREB was found to be involved in regulating MBP expression in response to elevated 
cyclic AMP (Sato-Bigbee and DeVries, 1996, Afshari et al., 2001). These findings 
suggest that CREB is a mediator of multiple signals that modulate the extent of 
oligodendrocyte development and myelination. Nevertheless, it remains to be 
determined whether buprenorphine-mediated activation of the μ-opioid receptor and its 
effect on CREB phosphorylation may be part of the signaling cascade underlying the 
effects of this drug on axonal growth and myelination observed in the present studies.
It is important to stress that while this thesis investigated the perinatal effects of 
therapeutic doses of buprenorphine, supra-therapeutic drug levels may have very 
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different effects and also work through distinct mechanisms. As described before, recent 
studies from our laboratory have demonstrated that animals exposed to a therapeutic 
dose of buprenorphine exhibited elevated MBP expression (Sanchez et al., 2008, 
Eschenroeder et al., Manuscript under review), increased complexity of oligodendrocyte 
morphology, and a greater proportion of pre-oligodendrocytes that could become 
mature oligodendrocytes (Eschenroeder et al., Manuscript under review). These 
findings suggested that low doses of buprenorphine accelerate oligodendrocyte 
differentiation. Conversely, supra-therapeutic doses of buprenorphine induce opposite 
effects, namely decreased MBP expression (Sanchez et al., 2008, Eschenroeder et al., 
manuscript under review), simpler oligodendrocyte morphology, and fewer pre-
oligodendrocytes that could mature into oligodendrocytes (Eschenroeder et al., 
manuscript under review). These findings indicated that higher doses of buprenorphine 
delay oligodendrocyte development.
Further studies indicated that the bell-shaped dose-dependent effect of buprenorphine 
on oligodendrocyte differentiation could be attributed to the involvement of different 
opioid receptors. As discussed above, the stimulatory actions on oligodendrocyte 
maturation exerted by low dose buprenorphine involve the μ-opioid receptor. At high 
doses, however, the results indicated that buprenorphine also works through the 
nociceptin/orphanin FQ receptor (NOP), a G protein-coupled receptor known to be 
involved in pain regulation but never before implicated in the regulation of 
oligodendrocyte development (Eschenroeder et al., Manuscript under review). 
Importantly, those studies showed that buprenorphine effects mediated by the NOP 
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receptor were able to counteract the positive actions on cell development mediated by 
the μ-opioid receptor. Thus, buprenorphine dose-dependent effects uncovered novel 
and opposing roles of the μ-opioid- and NOP receptors in CNS development. The 
results suggested that balance between signaling mediated by μ-opioid receptor 
activation and a novel, yet unidentified pathway that includes the NOP receptor, plays a 
crucial role in the timing of oligodendrocyte maturation and myelin synthesis 
(Eschenroeder et al, 2011). It is important to point out that the above mechanisms of 
buprenorphine signaling were mainly based on the effects if this drug on cultured 
oligodendrocytes.
Oligodendrocyte differentiation, however, is not the only factor that determines the onset 
of myelination. Studies of the optic nerve have demonstrated that while oligodendrocyte 
differentiation occurs in the rostro-caudal direction, myelination proceeds in the opposite 
direction. Results from these studies suggested that axonal diameter was acting as an 
additional signal to determine the initiation of myelination (Colello et al., 1995). As 
discussed previously, there is well-established bi-directional signaling between axons 
and oligodendrocytes that could be influenced by buprenorphine, causing accelerated 
myelination in exposed animals.
It is possible to hypothesize that accelerated oligodendrocyte maturation induced by 
therapeutic doses of buprenorphine may result in increased myelin compaction by a 
mechanism dependent on MAG. As already indicated, previous results from our 
laboratory have demonstrated that perinatal exposure to therapeutic buprenorphine 
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doses causes an early  increase in MAG glycosylation and interaction with Fyn (Sanchez 
et al., 2008). Besides the already  established role of MAG in initiating axo-glial 
interactions, several lines of evidence have suggested that this molecule also plays a 
role in myelin stability. Studies conducted in MAG-null mice have shown that these 
animals exhibit structural abnormalities in the periaxonal region, such as reduced 
oligodendroglial cytoplasm in the inner myelin sheath, and separation of this sheath 
from the axon (Li et al., 1994, Montag et al., 1994, Ma et al., 2003). In aging mutant 
mice, axons exhibited a decreased caliber, reduced NF spacing, and an increased 
incidence of degeneration (Pan et al., 2005). However, the mechanisms underlying 
MAG effects on myelin compaction or stability are not clear. Recent studies have 
investigated the role of gangliosides, a family  of glycosphingolipids that contain sialic 
acid and are expressed on the neuronal plasma membrane (Schnaar, 2007). It is 
thought that gangliosides, such as GD1a and GT1b, are receptors for MAG (Yang et al., 
1996, Vyas and Schnaar, 2001). Studies with B4galnt1 mutant mice, which are 
incapable of synthesizing these complex gangliosides, exhibit axonal degeneration, 
decreased NF spacing, and decreased axonal caliber (Sheikh et al., 1999, Chiavegatto 
et al., 2000). Interestingly, this resembles the morphology of MAG-null mice, suggesting 
that interaction of MAG with GD1a or GT1b could be part of the mechanism that 
influences both myelin stability and axonal caliber. Based on these findings, it can be 
speculated that the buprenorphine-induced elevation in MAG glycosylation and 
interaction with Fyn could be facilitating myelin stability, thus increasing the proportions 
of axons in the spinal cord exhibiting compacted myelin.
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It is also very likely that increased proportion of axons with compacted myelin observed 
in the buprenorphine-exposed animals is a direct result of the accelerated and 
augmented expression of MBP (Sanchez et al., 2008, Eschenroeder et al., Manuscript 
under review). As described above, MBP has been implicated in initiating (Privat et al., 
1979, Readhead et al., 1987) and also maintaining myelin compaction (Matthieu et al., 
1986). Because low buprenorphine doses appear to accelerate oligodendrocyte 
development, it is also reasonable to hypothesize that in addition to MAG and MBP, 
other myelin components important for myelin formation and compaction may also be 
increased. Among these could be PLP and galactocerebrosides. Besides being a major 
myelin component, several lines of evidence have demonstrated that PLP affects myelin 
stability, since knockout animals exhibit an abnormal intraperiod line (Duncan et al., 
1987, Klugmann et al., 1997). Glactocerebroside (GalC) and its sulfated derivative, 
sulfatide, which are major lipid components of myelin, also have a well-established role 
in myelin stability (Coetzee et al., 1996, Coetzee et al., 1998, Dupree et al., 1998, 
Marcus et al., 2002, Marcus et al., 2006). Thus, it would be important to determine 
whether buprenorphine may induce a general increase in the expression of all myelin 
components or on the other hand, have specific effects on selective molecules which 
like MAG and MBP are crucial to myelin compaction.  
Certainly, analysis of myelin compaction in the spinal cord has yielded very significant 
differences between buprenorphine-treated animals and controls. However, it is 
important to acknowledge the possibility that fixation artefacts could account for some 
axons to be characterized as exhibiting “uncompacted” or “partially compacted” myelin. 
 83
It is possible that to a certain extent, some of these axons may actually exhibit 
compacted myelin, but significant portions of the myelin lamellae were separated during 
the fixation procedure, giving the appearance of myelin that had not yet been 
compacted. It remains controversial whether there is a biological reason for this, one 
may hypothesize that such artefacts could occur because immature myelin may be still 
"loosely" compacted and therefore more susceptible to disarray during fixation.
Overall, investigations into actions of this drug prove to be difficult, particularly  because 
some of the observed effects may be due to its active metabolite, norbuprenorphine 
(Robinson, 2002a). Additionally, our limited understanding of normal radial growth and 
myelination in the CNS further complicate the issue, and we acknowledge the possibility 
that other unknown mechanisms may also play a role in mediating the effects of 
buprenorphine. Effects on myelination in vivo may also likely involve indirect effects 
mediated by buprenorphine actions on other CNS cells such as astrocytes or microglia, 
which may potentially modulate myelination. One may also speculate that there are 
direct effects on neurons, as suggested by  previous studies from Dr. Susan Robinsonʼs 
laboratory, which indicate that there are buprenorphine-induced delays in neuronal 
development in the striatum (Robinson, 2002b).
Ironically, although the biological complexity of the system apparently hinders our 
investigations, these pharmacological studies will eventually provide us with insight into 
normal developmental processes. In summary, the present studies provide further 
evidence on the potential effects of buprenorphine on myelination in the maturing brain 
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and now extend these actions to the spinal cord. Together with our previous findings, 
these observations stress the importance of opioid signaling during CNS development. 
Ultimately, it is our hope that the information gained from these studies will help  to 
design safer treatment protocols for pregnant opioid addicts, minimizing deleterious 
effects in both mothers and babies. Additionally, these studies may also shed light unto 
mechanisms that play a role in demyelinating diseases, such as multiple sclerosis in the 
CNS or Charcot-Marie-Tooth disease in the PNS.
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